Payment overview · 2025
General Payments
$502.48
25 reported records · 12 companies
Healthcare provider profile · identity verified
Jayesh M Madhani, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · WHITING, IN · NPI 1457461576
Verified facts
What the public records show
CMS Open Payments records show Jayesh M Madhani, MD received $502.48 in general payments during 2025 across 25 reported records.
Dexcom, Inc. accounted for 18.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Verquvo.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Mounjaro by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 233 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $90.34 | 18.0% | 5 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $72.30 | 14.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $70.03 | 13.9% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $41.44 | 8.2% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $40.52 | 8.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.15 | 8.0% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $38.62 | 7.7% | 2 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $26.65 | 5.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $23.90 | 4.8% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $21.05 | 4.2% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $20.33 | 4.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.15 | 3.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.48 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $90.34 | 5 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $72.30 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $70.03 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.44 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $40.52 | 2 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $39.16 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $38.62 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $21.05 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $20.71 | 1 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $20.33 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $19.44 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $17.15 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 79 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 27 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 233 | exact normalized | Medicare Part D |
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
79 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
27 | 12 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
233 | 40 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 374 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 289 | 113 |
| Ozempic | Semaglutide | 233 | 40 |
| Furosemide | Furosemide | 189 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 173 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 170 | 64 |
| Pantoprazole Sodium | Pantoprazole Sodium | 169 | 73 |
| Losartan Potassium | Losartan Potassium | 165 | 62 |
| Eliquis | Apixaban | 146 | 44 |
| Metformin Hcl | Metformin Hcl | 117 | 50 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 43 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 107 | 41 |
| Lisinopril | Lisinopril | 107 | 43 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 93 | 60 |
| Levothyroxine Sodium | Levothyroxine Sodium | 88 | 29 |
| Potassium Chloride | Potassium Chloride | 85 | 35 |
| Carvedilol | Carvedilol | 79 | 30 |
| Farxiga | Dapagliflozin Propanediol | 79 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 78 | 29 |
| Hydralazine Hcl | Hydralazine Hcl | 75 | 32 |
| Ranolazine Er | Ranolazine | 61 | 16 |
| Alcohol Pads | Alcohol Antiseptic Pads | 60 | suppressed |
| Nifedipine Er | Nifedipine | 60 | 23 |
| Alprazolam | Alprazolam | 59 | 20 |
| Clonidine Hcl | Clonidine Hcl | 58 | 17 |
| Allopurinol | Allopurinol | 57 | 23 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 18 |
| Clopidogrel | Clopidogrel Bisulfate | 51 | 22 |
| Spironolactone | Spironolactone | 50 | 21 |
| Januvia | Sitagliptin Phosphate | 45 | 12 |
| Entresto | Sacubitril/Valsartan | 44 | 15 |
| Ezetimibe | Ezetimibe | 44 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 41 | suppressed |
| Simvastatin | Simvastatin | 41 | 14 |
| Hydrochlorothiazide | Hydrochlorothiazide | 40 | 18 |
| Glipizide | Glipizide | 39 | 14 |
| Montelukast Sodium | Montelukast Sodium | 39 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 38 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 31 |
| Gabapentin | Gabapentin | 35 | 16 |
| Tramadol Hcl | Tramadol Hcl | 35 | 18 |
| Nitroglycerin | Nitroglycerin | 32 | 18 |
| Azithromycin | Azithromycin | 31 | 24 |
| Omeprazole | Omeprazole | 31 | 14 |
| Enalapril Maleate | Enalapril Maleate | 30 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Jardiance | Empagliflozin | 27 | 12 |
| Cephalexin | Cephalexin | 26 | 22 |
| Clonidine | Clonidine | 26 | suppressed |
| Lidocaine | Lidocaine | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 25 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 23 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Famotidine | Famotidine | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 21 |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 21 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Prednisone | Prednisone | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | 11 |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Minoxidil | Minoxidil | 14 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | 12 |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 12 | suppressed |
| Telmisartan | Telmisartan | 12 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.48 · 25 records | Dexcom, Inc. | CAPVAXIVE, CARDIOMEMS, Dexcom G6 Transmitter, FARXIGA, Flexitouch Plus, JARDIANCE, LifeVest, MOUNJARO, Nimbl, Ozempic, REPATHA, REZDIFFRA, VERQUVO, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error